CHINA - China Animal Healthcare Ltd said its subsidiary, Shenzhou Pagina-kang Technology Co Ltd has agreed to buy Jianxiang Hemu from its four shareholders for a total of RMB210 million (S$43.44 million).
According to The Business Times, the sale price took into consideration, amongst other factors, the potential of the vaccine for porcine reproductive respiratory syndrome developed by Jianxiang.
China Animal said the board feels the acquisition is in the best interest of the group and will further expand the range of its biological animal drug products, which include vaccines for swine fever and other livestock vaccines for immunisation against common diseases and viruses.
